• Molecular NameIbandronate
  • Synonymibandronate; Ibandronate sodium; Ibandronate sodium monohydrate; Ibandronic Acid; R484
  • Weight319.231
  • Drugbank_IDDB00710
  • ACS_NO114084-78-5
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-2.74
  • pka2.0
  • LogD (pH=7, predicted)-6.85
  • Solubility (experiment)Soluble
  • LogS (predicted, ACD/Labs)(ph=7)0.5
  • LogSw (predicted, AB/LogsW2.0)269.5
  • Sw (mg/ml) (predicted, ACD/Labs)191.53
  • No.of HBond Donors5
  • No.of HBond Acceptors8
  • No.of Rotatable Bonds9
  • TPSA158.15
  • StatusFDA approved
  • AdministrationOral, intravenous
  • PharmacologyA potent bisphosphonate drug used in the prevention and treatment of osteoporosis.
  • Absorption_valueN/A
  • Absorption (description)Poorly absorbed (mean bioavailability following a 2.5 mg oral dose is about 0.6% compared to intravenous dosing). Absorption is impaired by any kind of food or drink other than plain water.
  • Caco_2N/A
  • Bioavailability1.0
  • Protein binding95.2
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmNo evidence of ibandronate being metabolized in humans.
  • Half life10~60 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySide effects include bronchitis, pneumonia and urinary tract infections.
  • LD50 (rat)LD50=811 mg/kg
  • LD50 (mouse)N/A